Arrowhead Pharmaceuticals Q2 2022 Earnings Report
Key Takeaways
Arrowhead Pharmaceuticals reported a net income of $44.366 million and revenue of $151.805 million for the fiscal second quarter ended March 31, 2022.
Initiated the PALISADE Phase 3 clinical study to evaluate the efficacy and safety of ARO-APOC3 in adults with familial chylomicronemia syndrome.
Completed enrollment of 204 patients in the Phase 2b ARCHES-2 clinical study of ARO-ANG3 for patients with mixed dyslipidemia.
Initiated the Phase 2 GATEWAY clinical study of ARO-ANG3 in patients with homozygous familial hypercholesterolemia (HoFH).
Initiated a Phase 1/2 study of ARO-C3 for various complement mediated diseases.
Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals
Forward Guidance
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995.